Hepatitis B InfectionNCIt concept

https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=1365
2024
France
public health guidelines
"u" lymphocyte
Sells
Cell
transplant, nos
Hepatitis B Infection
cells
organ donor, nos
tissue donors
hepatitis B
Hepatitis C Virus
Million Cells
Cancell
Organ Transplantation
hepatitis C
Cell Count
organ donors
Organ Donor
Tissue
type b viral hepatitis
viral hepatitis c
Hepatitis C Infection
transplants

---
https://www.rp2s.fr/wp-content/uploads/2024_HepB_18mars.pdf
2024
France
guideline
Unknown Site of New Tumor Event
Not Known if Peripheral Blood Immunophenotyping and Cytochemistry Were Performed
Unknown if Medication Taken
Adjuvant Post-operative Targeted Molecular Therapy Administration Unknown
1p/19q Codeletion Status Unknown
Not Known if NF1 Mutation Analysis Was Performed
Tumor Reoccurrence Unknown After Initial Treatment
Unknown History of Kawasaki Disease
Unknown Daily Fluid Intake
Unknown if Subsequent Known Primary Melanoma(s) Found During the Follow-Up
Not Known if EGFR Amplification Analysis Was Performed
Cancer History Unknown
Not Known if MGMT Promoter Methylation Testing Was Performed
Evidence of Disease Unknown after Completion of Therapy
Unknown History of Congenital Heart Disease
Average Daily Use Smokeless Tobacco after Use for Six Weeks Unknown
hepatitis surface antigen
Not Known if SDH Complex Mutation Analysis Was Performed
Hypertension Unknown
Stage Unknown
First Course Treatment Completion Measure of Success of Outcome Unknown
Unknown History of Alcohol Use
Not Known if KRAS Mutation Analysis Was Performed
Not Known if PDGFRA Mutation Analysis Was Performed
Unknown if Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event
Not Known if Fluorescence In Situ Hybridization Was Performed
Multiple Known Primary Tumors Unknown at Initial Melanoma Diagnosis
Unknown History of Gestational Complication
Not Known if MET Mutation Analysis Was Performed
Not Known if ALK Rearrangement Analysis Was Performed
surrogate mother
Not Known if 1p/19q Deletion Analysis Was Performed
Unknown Daily Salt Intake
Unknown History of Non-Cardiac Surgery
Not Known if Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed
Not Known if BRAF Mutation Analysis Was Performed
Tumor Progression Unknown After Initial Treatment
Sex Not Known
hepatitis B
Performance Status Scale Timing Unknown
Unknown if Chief Complaint was Witnessed
Not Known if BRAF Rearrangement Analysis Was Performed
Not Known if RET Rearrangement Analysis Was Performed
Unknown if Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event
History of Medical Treatment Unknown
Unknown Age When Started using Smokeless Tobacco after Regular Use
Adjuvant Post-operative Pharmaceutical Therapy Administration Unknown
Use of Smokeless Tobacco at Time of Diagnosis Unknown
Unknown GENC
Unknown Tamoxifen Use
New Tumor Event After Initial Treatment Unknown
Charge
Additional Surgery for New Tumor Event Unknown
Unknown Oral Contraceptive Use
birth, nos
Unknown if Chief Complaint Caused by Trauma
Unknown when Chief Complaint Present
Unknown History of Neonatal Complication
Not Known if Additional Molecular Studies Were Performed
Device Status Unknown
Adjuvant Post-operative Radiation Therapy Administration Unknown
parturition
Unknown if Patient Has Genetic Syndrome Associated with Congenital Heart Defect
Unknown if Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event
Not Known if PTEN Mutation Analysis Was Performed
Unknown Procedure Type for New Tumor Event
Not Known if 10q23/PTEN Locus Deletion Analysis Was Performed
Adjuvant Post-operative Immunological Therapy Administration Unknown
Unknown History of Illicit Drug Use
Unknown if Routine Cytogenetics were Completed
Unknown Clark Level
Immunotherapy Status Unknown
hepatitis B surface antigens
Unknown Family History Cardiovascular Disease or Cardiovascular Disease Risk Factors
Regular Smokeless Tobacco Use for Six Weeks or More Unknown
Unknown Transformation
Additional Surgery for New Loco-Regional Tumor Event Unknown
Unknown History of Rheumatic Fever
Unknown if Interferon Gamma Treatment was Administered Prior to Specimen Resection
Chemotherapy Status Unknown
Unknown Use of Menopausal Hormone Therapy
Chemical/Occupational Exposure Type Unknown
Unknown Number of Full Term Pregnancies
Unknown if Another form of Birth Control was Used
Not Known if IDH Family Mutation Analysis Was Performed
Chemical/Occupational Exposure History Unknown
Not Known if Lymph Node Dissection Was Performed
Unknown Molecular Analysis
Not Known if EGFR Mutation Analysis Was Performed
Molecular Abnormalities Unknown
Unknown if Caffeine Consumption is Routine
surrogate mothers
Not Known if NRAS Mutation Analysis Was Performed
patient care management
Not Known if ROS1 Rearrangement Analysis Was Performed
Unknown if Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event
Unknown History of Myopathy
Unknown Release Mechanism of Action
Unknown Daily Caloric Intake
Not Known if KIT Mutation Analysis Was Performed
Tumor Location Unknown
type b viral hepatitis
Adjuvant Post-operative Chemotherapy Administration Unknown
Documentation Unknown
Unknown if New Disease is Multifocal
Additional Surgery for New Metastatic Tumor Event Unknown
Unknown Dosage Form Category
Physician Diagnosed Diabetes Unknown
Hepatitis B Infection
Birth Time
Unknown Route of Administration
Follow-Up Form Completion Outcome Measure of Success Unknown
Paraneoplastic Syndrome Status is Unknown
Tumor Laterality Unknown
Not Known if Additional Immunohistochemistry Was Performed
Unknown if Radiation Was Administered as an Additional Treatment for a New Tumor Event
Intercurrent Illness is Unknown at Onset of Chief Complaint
Not Known if TP53 Mutation Analysis Was Performed
Unknown History of Other Muscular Dystrophy or Glycogen Storage Disorder
Not Known if ERBB2 Mutation Analysis Was Performed
Unknown if Patient was Previously Evaluated for Current Chief Complaint
Birth Month
Not Known if ATRX Mutation Analysis Was Performed
Interferon Gamma Treatment Administration 90 Days Prior to Specimen Resection Unknown

---
https://www.canada.ca/fr/sante-publique/services/rapports-publications/soins-primaires-hepatite-b-aide-memoire.html
2014
Canada
guideline
ADM wt Allele
Hepatitis B Infection
ATF7IP wt Allele
Without Help
hepatitis B
primary health care
Memory
type b viral hepatitis
memory, nos
AM Mouse
Single-Stranded DNA Cytosine Deaminase
Memory Device
Americium
nursing
AICDA wt Allele
memory
hepatitis b virus
AH Receptor-Interacting Protein
Primary Care
Armenia
primary health care
principal
With Some Help
AIP Gene
Acute Interstitial Pneumonia
Atherogenic Index of Plasma
Attometer
Assistance

---